Gapping up
News:
- NKTX +12.7% (prices $240 mln offering consisting of common stock and warrants)
- ATXS +12.4% (initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215)
- MASI +12.1% (authorizes management to evaluate a proposed separation of its consumer business; reaffirms Q1 an FY24 guidance; Politan confirmed it nominates two independent candidates for Masimo Board)
- MBRX +10.4% (Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial)
- BDSX +7.2% (entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer)
- AXSM +6.5% (announces AXS-12 achieves primary endpoint in the symphony Phase 3 trial in narcolepsy)
- DWAC +6% (stockholders confirmed approval the proposed merger with Trump Media & Technology Group Corp)
- ACET +2.3% (enters into an Open Market Sales Agreement to sell shares its common stock)
- CNXC +2.2% (files for 13,166,053 share common stock offering by selling shareholders)
- UTHR +2.1% (announces $1 billion accelerated share repurchase program)
- BITF +1.3% (announces CEO transition; reiterates 2024 YE guidance of 21 EH/s and 21 w/TH)
- CCO +1.2% (announces Clear Channel International B.V.'s new term loan facility and concurrent redemption of existing secured notes)
- DIS +1.2% (Blackwells Capital believes Nelson Peltz is Not the Change Disney's Board Needs; also upgraded to Overweight from Equal Weight at Barclays)
Analyst comments:
- GDRX +6.1% (upgraded to Overweight from Equal Weight at Wells Fargo)
- FL +3.3% (upgraded to Outperform from In-line at Evercore ISI)
- TPX +2.1% (upgraded to Buy from Hold at Loop Capital)
- CAR +1.8% (upgraded to Buy from Neutral at Northcoast)
- HUYA +1.1% (upgraded to Buy from Neutral at BofA Securities)